Journal Watch · Frontiers in Immunology · 2026
Circular RNA therapeutics: a new class of long-acting RNA medicines for oncology, immunology, and rare diseases.
Finally, we propose priorities for the field: standardised purity and identity assays, head-to-head platform comparisons, mechanistic immunoprofiling, and indication-focused early clinical development.
TL;DR
Finally, we propose priorities for the field: standardised purity and identity assays, head-to-head platform comparisons, mechanistic immunoprofiling, and indication-focused early clinical development.
Key findings
- We introduce a decision-oriented three-axis framework to delineate settings in which circRNA plausibly offers added value (for example, single-dose local protein depots; durable antigen expression for selected vaccine strategies) versus contexts where evidence remains preliminary or advantages may diminish when compared against optimised mRNA/self-amplifying RNA (saRNA) comparators.
- We also highlight emerging computational models that may accelerate circRNA target and drug-sensitivity discovery.
- Finally, we propose priorities for the field: standardised purity and identity assays, head-to-head platform comparisons, mechanistic immunoprofiling, and indication-focused early clinical development.
What they did
Consequently, broad claims such as 'circRNA is less immunogenic than mRNA' are unreliable without rigorous, standardised benchmarking. This narrative review provides a conceptually grounded, evidence-informed synthesis of recent advances in synthetic (exogenous) circRNA therapeutics across oncology, immunology (including vaccines), and rare/chronic diseases. We combine structured literature identification (2018-November 2025) with qualitative appraisal of preclinical and early translational studies, focusing on: (i) platform engineering (circularisation, purification, translation elements, and delivery); (ii) therapeutic modality (protein-coding versus regulatory circRNAs and programmable circuits); (iii) disease-domain use cases; and (iv) unresolved controversies and translational constraints.
Full abstract (original)
Background: Circular RNAs (circRNAs) have progressed from being viewed as splicing by-products to emerging therapeutic constructs with a distinct pharmacology. Their covalently closed topology can increase RNA stability, prolong intracellular persistence, and under some conditions sustain translation relative to matched linear RNAs. However, circRNA performance and immunogenicity depend strongly on the circularisation chemistry, impurity profiles (linear RNA and double-stranded RNA (dsRNA) by-products), sequence and structural features, and the delivery formulation.
What they did: Consequently, broad claims such as 'circRNA is less immunogenic than mRNA' are unreliable without rigorous, standardised benchmarking. This narrative review provides a conceptually grounded, evidence-informed synthesis of recent advances in synthetic (exogenous) circRNA therapeutics across oncology, immunology (including vaccines), and rare/chronic diseases. We combine structured literature identification (2018-November 2025) with qualitative appraisal of preclinical and early translational studies, focusing on: (i) platform engineering (circularisation, purification, translation elements, and delivery); (ii) therapeutic modality (protein-coding versus regulatory circRNAs and programmable circuits); (iii) disease-domain use cases; and (iv) unresolved controversies and translational constraints.
Results & conclusions: We introduce a decision-oriented three-axis framework to delineate settings in which circRNA plausibly offers added value (for example, single-dose local protein depots; durable antigen expression for selected vaccine strategies) versus contexts where evidence remains preliminary or advantages may diminish when compared against optimised mRNA/self-amplifying RNA (saRNA) comparators. We also highlight emerging computational models that may accelerate circRNA target and drug-sensitivity discovery. Finally, we propose priorities for the field: standardised purity and identity assays, head-to-head platform comparisons, mechanistic immunoprofiling, and indication-focused early clinical development.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1758902 · PubMed 42023247.
Why it matters for pharma & biotech
- Directly relevant to teams in mRNA / delivery technology, vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: mRNA / delivery technology · vaccines
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
Finally, we propose priorities for the field: standardised purity and identity assays, head-to-head platform comparisons, mechanistic immunoprofiling, and indication-focused early clinical development.
What type of study is this?
It is a review / perspective, published in Frontiers in Immunology in 2026. Consequently, broad claims such as 'circRNA is less immunogenic than mRNA' are unreliable without rigorous, standardised benchmarking.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1758902. PubMed ID: 42023247. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/circular-rna-therapeutics-a-new-class-of-long-acting-rna-medicines-for-o-758902/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides